profit from every SGD 100 of sales.
SGD 0SGD 100
Haw Par
SGD 12.51-1.26% today
-19.7% since Dec 19, 25
1-year low SGD 12.511-year high SGD 18.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay SGD 10.43 for every SGD 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Haw Par vs. similar companies
Haw Par grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from SGD 100 of sales | Sales growth a year | Price per SGD 1 of profit |
|---|---|---|---|
| Haw Par | 10.4× · Cheap | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Haw Par's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 10.4×
- –
- 0.49
- 0.8×
- 12.0×
- 50.3×
- –
- 2.0%
- 9.6%
- –
Profitability
- –
- 29.2%
- 115.4%
- –
- 5.4%
- 4.9%
- –
- –
- –
- –
Growth
- +8.1%
- +21.4%
- –
- –
- +0.0%
Financial health
- -2.6×
- 0.01
- –
- 185.9×
- 52.24
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 946
Top 11%of 872
Top 10%of 563
Bottom 39%of 868
Top 43%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
97Pass
Philip Fisher
68Pass
Peter Lynch
83Pass
Joel Greenblatt
50No pass
Charlie Munger
62Pass
Terry Smith
49No pass
Questions about Haw Par
Is Haw Par a good stock to buy?
A strong, very profitable business, and the price looks low. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Haw Par AI analysis
What does Haw Par do?
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It is in Drug Manufacturers - General.
Is Haw Par stock halal?
Yes. Haw Par passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
Who are Haw Par's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Haw Par's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.